Pioglitazone for Heroin and for Nicotine Dependence

Stopped early · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Heroin Dependence, Nicotine Dependence

In brief

The goal of the proposed research is to improve the effectiveness of treatments for opioid and for nicotine dependence by testing a novel pharmacological strategy. Specifically, pioglitazone, a peroxisome proliferator-activated gamma receptor (PPARγ) agonist, will be used as an adjunct to agonist-based treatment.

Key facts

Study ID

NCT01395797

Run by

New York State Psychiatric Institute

People needed

82

Starts

2011-03-01

Expected to finish

2014-06-01

Last updated by the study team

2017-07-13

Who can join

Age: 21 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 21-55 years of age
• Physically healthy
• Able to perform study procedures

You may not qualify if…

• Pregnancy
• Physical dependence on any other drugs besides caffeine, heroin and nicotine

Where it is running

• New York State Psychiatric Institute — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.